<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02795429</url>
  </required_header>
  <id_info>
    <org_study_id>CINC280X2108</org_study_id>
    <secondary_id>2015-005417-76</secondary_id>
    <nct_id>NCT02795429</nct_id>
  </id_info>
  <brief_title>Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC</brief_title>
  <official_title>A Phase Ib/II, Open-label, Multi-center Study of INC280 in Combination With PDR001 or PDR001 Single Agent in Advanced Hepatocellular Carcinoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study of INC280 and PDR001 is to characterize the safety, tolerability,&#xD;
      pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of PDR001 administered&#xD;
      i.v. as a single agent or in combination with INC280 administered orally in adult patients&#xD;
      with advanced hepatocellular carcinoma (HCC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 15, 2016</start_date>
  <completion_date type="Actual">June 24, 2021</completion_date>
  <primary_completion_date type="Actual">June 1, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>During the first 2 cycles (42 days) of treatment (Phase Ib)</time_frame>
    <description>To identify the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)</measure>
    <time_frame>From cycle 1, every 6 weeks up to cycle 12, then every 3 cycles until progression of disease per irRC or patient withdrawal, for up to 3 years (Phase II)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best overall response (BOR)</measure>
    <time_frame>From cycle 1, every 6 weeks up to cycle 12, then every 3 cycles until progression of disease per irRC or patient withdrawal, for up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of overall response (DOR)</measure>
    <time_frame>Baseline, every 6 weeks until progression, for up to 3 years (Phase II)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR)</measure>
    <time_frame>Baseline, every 6 weeks until response (Phase II), for up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Baseline, every 6 weeks until progression for up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP)</measure>
    <time_frame>Baseline, every 6 weeks until progression for up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Every 12 weeks until the end of study for up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Baseline, every 6 weeks until progression for up to 3 years (Phase Ib)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area under the plasma concentration versus time curve (AUC) (INC280)</measure>
    <time_frame>Day 1 of the first 6 cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Area under the serum concentration versus time curve (AUC) (PDR001)</measure>
    <time_frame>Days 1, 2, 3, 4, 8, 11 and 15 of Cycles 1 and 3, Day 1 of Cycles 2, 4, 5 and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Peak Plasma Concentration (Cmax) (INC280)</measure>
    <time_frame>Day 1 of the first 6 cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK:Time of Maximum concentration observed (Tmax) (INC280)</measure>
    <time_frame>Day 1 of the first 6 cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Peak Serum Concentration (Cmax) (PDR001)</measure>
    <time_frame>Days 1, 2, 3, 4, 8, 11 and 15 of Cycles 1 and 3, Day 1 of Cycles 2, 4, 5 and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Time of Maximum concentration observed (Tmax) (PDR001)</measure>
    <time_frame>Days 1, 2, 3, 4, 8, 11 and 15 of Cycles 1 and 3, Day 1 of Cycles 2, 4, 5 and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitation of tumor infiltrating lymphocytes (TILs)</measure>
    <time_frame>Baseline, 6-9 weeks after start of study treatment (if feasible)</time_frame>
    <description>Quantitation of TILs will be assessed by CD8 immunohistochemistry (IHC) within the tumor area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Programmed death ligand 1 (PD-L1) protein expression in tumor cells</measure>
    <time_frame>Baseline, 6-9 weeks after start of study treatment (if feasible)</time_frame>
    <description>Expression of PD-L1 will be measured on tumor cells by immunohistochemistry (IHC)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Advanced Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>INC280+PDR001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PDR001 + INC280 treatment in Phase II</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PDR001 single agent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PDR001 single agent treatment in Phase II</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PDR001</intervention_name>
    <description>PDR001 will be administered intravenously</description>
    <arm_group_label>INC280+PDR001</arm_group_label>
    <arm_group_label>PDR001 single agent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INC280</intervention_name>
    <description>INC280 will be administered orally</description>
    <arm_group_label>INC280+PDR001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically documented locally advanced recurrent or metastatic&#xD;
             HCC or for patients with cirrhosis according to the American Association for the Study&#xD;
             of Liver Diseases (AASLD) and Asian Pacific Association for the study of the liver&#xD;
             (APASL) criteria. Current cirrhotic status of Child Pugh Class A (5-6 points), with no&#xD;
             encephalopathy and/or clinically significant ascites (defined as requiring the use of&#xD;
             diuretics or paracentesis treatment).&#xD;
&#xD;
          2. Patients must have received prior systemic sorafenib treatment for HCC with documented&#xD;
             progression during or after discontinuation of sorafenib treatment (for France only:&#xD;
             patients must have received at least 8 weeks of prior sorafenib treatment), or are&#xD;
             intolerant to sorafenib (defined as documented Grade 3 or 4 adverse events that led to&#xD;
             sorafenib discontinuation),.&#xD;
&#xD;
          3. ECOG Performance Status â‰¤ 1.&#xD;
&#xD;
          4. Willing and able to swallow and retain oral medication. Other protocol defined&#xD;
             Inclusion criteria may apply.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of any live vaccines within 4 weeks of initiation of study treatment.&#xD;
&#xD;
          2. History of severe hypersensitivity reactions to other monoclonal antibodies (mAbs).&#xD;
&#xD;
          3. Clinically significant pleural effusion that either required pleurocentesis or is&#xD;
             associated with shortness of breath.&#xD;
&#xD;
          4. Active autoimmune disease or a documented history of autoimmune disease.&#xD;
&#xD;
          5. Clinically significant, uncontrolled heart diseases.&#xD;
&#xD;
          6. Patient having out of range laboratory values defined as:&#xD;
&#xD;
               -  Total bilirubin &gt; 2 mg/dL, except for patients with Gilbert's syndrome who are&#xD;
                  excluded if total bilirubin &gt; 3.0 x ULN or direct bilirubin &gt; 1.5 x ULN&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) &gt; 5 x ULN&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) &gt; 5 x ULN&#xD;
&#xD;
               -  Coagulation: Prothrombin Time (PT) &gt; 4 seconds more than the ULN or International&#xD;
                  Normalized Ratio (INR) &gt; 1.7&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &lt; 1.5 x 109/L&#xD;
&#xD;
               -  Platelet count &lt; 75 x 109/L&#xD;
&#xD;
               -  Hemoglobin &lt; 9 g/dL&#xD;
&#xD;
               -  Creatinine clearance (calculated using Cockcroft-Gault formula, or measured) &lt; 45&#xD;
                  mL/min&#xD;
&#xD;
               -  Asymptomatic serum amylase grade &gt; 2 (1.5-2.0 x ULN). Patients with grade 1 or&#xD;
                  grade 2 serum amylase at the beginning of the study must be confirmed to have no&#xD;
                  signs or symptoms suggesting pancreatitis or pancreatic injury (e.g., elevated&#xD;
                  P-amylase, abnormal imaging findings of pancreas, etc.)&#xD;
&#xD;
               -  Serum lipase &gt; ULN&#xD;
&#xD;
               -  Potassium, Magnesium, Phosphorus, total Calcium (corrected for serum albumin)&#xD;
                  outside of normal limits (patients may be enrolled if corrected to within normal&#xD;
                  limits with supplements during screening)&#xD;
&#xD;
        Other protocol-defined Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montpellier cedex 5</city>
        <state>Herault</state>
        <zip>34059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rozzano</city>
        <state>MI</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Modena</city>
        <state>MO</state>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tainan</city>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>China</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 17, 2016</study_first_submitted>
  <study_first_submitted_qc>June 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2016</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase Ib/II</keyword>
  <keyword>INC280</keyword>
  <keyword>PDR001</keyword>
  <keyword>checkpoint inhibitor</keyword>
  <keyword>PD-1</keyword>
  <keyword>Liver cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spartalizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

